Atherosclerosis News and Research

RSS

Atherosclerosis is the progressive buildup of plaque - the fatty deposits and other cells - in the inner walls of the arteries. The condition is a consequence of elevated cholesterol and for many it's a silent disease, with no visible signs or symptoms. The disease can begin in early adulthood and continues to progress for the rest of a person's life. Despite the serious nature of atherosclerosis, many people do not understand how it develops and progresses.

Recruitment of Phase II trial of TB-402 completed ahead of schedule

ThromboGenics NV and co-development partner BioInvent International announce that they have completed recruitment of their Phase II trial of TB-402 ahead of schedule.

28 Oct 2009

$Cardiovascular disease may increase hip fracture incidence$

Cardiovascular disease may increase hip fracture incidence

A study that includes twins finds that the risk of hip fracture was significantly increased following a diagnosis of cardiovascular disease (CVD), with analysis also suggesting a genetic predisposition to the development of CVD and fractures, according to a study in the October 21 issue of JAMA.

26 Oct 2009

Low adiponectin levels may increase sepsis related complications

A new Canadian study has found that lower-than-normal levels of a naturally-occurring fat hormone may increase the risk of death from sepsis-an overwhelming infection of the blood which claims thousands of lives each year.

24 Oct 2009

LIVALO statin effective than simvastatin in reducing lipid levels

New Phase III data published today in "Current Medical Research and Opinion" highlight that the recommended starting dose of 2 mg of LIVALO (pitavastatin), a novel synthetic statin, was statistically superior to simvastatin at a dose of 20 mg over 12 weeks in reducing low-density lipoprotein cholesterol

22 Oct 2009

NicOx reports financial results for the first nine months of 2009

NicOx S.A. today reported financial results for the nine months ended September 30, 2009.

22 Oct 2009

AFFiRiS reports encouraging results from clinical studies of its two Alzheimer's vaccines

AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer's vaccines AD01 and AD02, which demonstrated favourable safety and tolerability profiles. These results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals.

21 Oct 2009

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

NicOx S.A. announced the presentation of detailed 26-week efficacy, safety and tolerability data from the second pivotal phase 3 study for naproxcinod (the 302 study) yesterday, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.

20 Oct 2009

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

AstraZeneca today announced the U.S. Food and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease.

19 Oct 2009

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

A genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure, according to a new study reported at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

14 Oct 2009

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").

14 Oct 2009

Increase in adiponectin hormone levels protects against sepsis-related mortality

A hormone naturally found in the fat that surrounds the abdominal organs for the first time has been linked to death related to sepsis, surgeons reported at the 2009 Clinical Congress of the American College of Surgeons. A study exhibited at the conference showed that low levels of the hormone adiponectin placed animals at a profoundly high risk of death from a septic insult.

14 Oct 2009

Galapagos extends collaboration with Merck to develop new therapies for atherosclerosis

Galapagos NV announced today that it has expanded its global strategic alliance in metabolic diseases with an affiliate of Merck & Co., Inc to incorporate the development of new therapies for atherosclerosis.

14 Oct 2009

Neighborhood may be a modifiable risk factor for diabetes

Individuals living in neighborhoods conducive to physical activity and providing access to healthy foods may have a lower risk of developing type 2 diabetes in a five-year period, according to a report in the October 12 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

13 Oct 2009

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

Eric Boerwinkle, Ph.D., a professor at The University of Texas Health Science Center at Houston, has received a $26 million federal stimulus grant to lead an effort to pinpoint genetic factors affecting the risk of heart, lung and blood diseases.

12 Oct 2009

New study to assess the risk of heart disease in diabetics

In a new international partnership, Dr. Randy Nelson, a researcher at Arizona State University's Biodesign Institute, and Dr. Tai E-Shyong , associate professor at Singapore's National University Hospital, National University Health System (NUHS), have teamed up to assess the risk of heart disease in diabetics with greater accuracy.

8 Oct 2009

FDA approves Daiichi Sankyo's sNDA for Welchol

Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.

7 Oct 2009

The Lewin Group issues recommendations to overcome barriers obstructing the lupus drug development

Today, The Lewin Group, a national health care consulting firm, issued recommendations on ways to overcome the barriers that have obstructed lupus drug development resulting in no new drug approval for this disease in more than 50 years - since the Eisenhower Administration.

From CSL Ltd 5 Oct 2009

Study finds an independent link between self-perceived psychological stress and stroke

Many patients urgently admitted to hospital with cerebral infarction state that they were under great stress over a prolonged period prior to suffering their stroke, is shown in a unique patient study conducted in cooperation between the Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital, Sweden.

3 Oct 2009

Arginetix raises funds for development programs

Arginetix, Inc. today announced it has closed a $10.75 million Series A financing. The company is developing small molecule inhibitors of the enzyme arginase for the treatment of endothelial dysfunction, including pulmonary arterial hypertension, atherosclerosis and asthma.

2 Oct 2009

Atherosclerosis News and Research

Further Reading

Recruitment of Phase II trial of TB-402 completed ahead of schedule

Cardiovascular disease may increase hip fracture incidence

Low adiponectin levels may increase sepsis related complications

LIVALO statin effective than simvastatin in reducing lipid levels

NicOx reports financial results for the first nine months of 2009

AFFiRiS reports encouraging results from clinical studies of its two Alzheimer's vaccines

NicOx presents data on its phase 3 naproxcinod study at the ACR meeting

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market

Increase in adiponectin hormone levels protects against sepsis-related mortality

Galapagos extends collaboration with Merck to develop new therapies for atherosclerosis

Neighborhood may be a modifiable risk factor for diabetes

Eric Boerwinkle receives $26 million federal stimulus grant to identify genetic factors influencing common diseases

New study to assess the risk of heart disease in diabetics

FDA approves Daiichi Sankyo's sNDA for Welchol

The Lewin Group issues recommendations to overcome barriers obstructing the lupus drug development

Study finds an independent link between self-perceived psychological stress and stroke

Arginetix raises funds for development programs

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News